Design with confidence
Design studies, profile compounds, and move from experimental questions to decision-ready outputs without waiting on fragmented specialist workflows.
Experimental decisions, unblocked
See how EMET supports preclinical teams focused on experimental design, compound profiling, and execution planning.
Preclinical capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Experimental Design
Design a validation study for our BRCA2 biomarker in triple-negative breast cancer - recommend the assay type, calculate the sample size for 80% power at p<0.05, define the control arms, and flag any confounds we need to account for.
Spatial Biology
Map the spatial distribution of TIGIT and PD-L1 co-expression across NSCLC tumor sections - identify immune-excluded vs inflamed microenvironments and flag which spatial clusters would be eligible for combination checkpoint blockade.
Lead Discovery & Compound Profiling
Given this SMILES, profile my EGFR T790M inhibitor candidate for physicochemical properties, ADMET liabilities, and structural alerts, and compare its drug-likeness to approved EGFR inhibitors.
CRISPR Screen Analysis & Synthetic Lethality
Analyze our genome-wide CRISPR screen from KRAS G12D pancreatic cancer cells (MAGeCK scores uploaded). Identify the top essential genes, find their synthetic lethal partners in SynLethDB, filter for druggability, and produce a prioritized hit list with existing compounds.
Lead Profiling & PK/PD Triage
Profile the druggability of PRMT5 as a cancer target - what is its Pharos development level, which inhibitors have published IC50 data, and what are the key ADMET liabilities for the leading scaffolds?
Frequently asked questions
Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.
Start free trial